IL17A and ankylosing spondylitis: The approval of secukinumab, a fully human monoclonal antibody able to neutralize IL-17A, has been a major advance in the treatment of ankylosing spondylitis.[18] Patients with ankylosing spondylitis are known to have high levels of this interleukin, which is critically involved in the pathogenesis of the disease.[19]